<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597142</url>
  </required_header>
  <id_info>
    <org_study_id>S2006</org_study_id>
    <nct_id>NCT00597142</nct_id>
  </id_info>
  <brief_title>A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.</brief_title>
  <acronym>RENAISSANCE</acronym>
  <official_title>A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate superior 9-month binary restenosis rate of the
      Express™ Renal Premounted Stent System as compared to an Objective Performance Criterion
      representative of PTRA, for atherosclerotic lesions in the aortorenal ostium.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binary in-stent restenosis rate of the Express™ Renal Stent at nine (9) months, defined by quantitative angiography.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success - &lt;30% residual diameter stenosis as visually assessed by the investigator without the occurrence of in-hospital MAE.</measure>
    <time_frame>Post stent deployment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization(TLR)*- Clinically driven reintervention of the target lesion through 9-months.</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization(TVR)* - Clinically driven reintervention of the target vessel through 9-months.</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (improvement) in renal function from pre-procedure to post-procedure, 1-month and 9-month followups</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal to Aortic Ratio, Resistive Index, and Peak Systolic Velocity using Ultrasound Core Lab values from pre-procedure to postprocedure and 9-months post-procedure.</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (improvement) in hypertension control from pre-procedure to post-procedure, 30-day and 9-month followups</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events (MAEs): device- or index procedure related death ,TLR, Significant Embolic Event through 9 months post-procedure</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success as visually assessed by the investigator.</measure>
    <time_frame>Immediately after stent deployment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Atherosclerotic Lesions in the Aortorenal Ostium</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Express™ Renal Premounted Stent System</intervention_name>
    <description>This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:
Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery
Lesion length ≤15mm
Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen
RVD 4.0-7.0mm</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for PTRA and stenting.

          -  One or more of the following: (1-3)

          -  Hypertension

          -  Recurrent &quot;flash&quot; pulmonary edema out of proportion to any impairment of left
             ventricular function

          -  Renal Dysfunction

          -  Single, de novo, or restenotic (from prior PTRA) atherosclerotic lesion in the ostium
             of the renal artery

          -  Lesion involving the aortorenal ostium or the leading edge of the stenosis is located
             within 5 mm of the opacified aortic lumen

          -  Renal Artery Stenosis: bilateral renal artery stenosis (one stent for one lesion in
             each renal artery) or unilateral renal artery stenosis, including a solitary
             functioning kidney

        Exclusion Criteria:

          -  Any previous or planned, surgery or percutaneous intervention ≤30 days prior to or
             after index procedure

          -  Advanced renal disease: serum creatinine &gt; 3.0 mg/dl

          -  End stage renal disease requiring dialysis; or previously diagnosed ephrosclerosis

          -  Recent vascular event ≤30 days pre-procedure (i.e. acute coronary syndrome,
             decompensated heart failure, transient ischemic attack or stroke.)

          -  Documented allergy or reaction to iodinated contrast media, including laryngeal edema,
             convulsions, profound hypotension,unresponsiveness, cardiopulmonary arrest, and
             clinically manifest arrhythmias (a mild allergy to contrast media that can be
             pretreated with medication is acceptable)

          -  Documented allergy to heparin, acetylsalicylic acid (ASA) or clopidogrel

          -  NYHA Class IV

          -  Bleeding diathesis

          -  Thrombocytopenia (platelets &lt; 100,000/mm3)

          -  Renal atrophy (renal length ≤ 8 cm determined by renal ultrasound)

          -  Patients requiring immunosuppressive therapy

          -  Renal allograft

          -  Stenosis location in a vascular graft or in a transplant artery Angiographic Exclusion

          -  Total occlusions

          -  Thrombus containing lesion

          -  Prior treatment of target lesion with stent (in-stent restenosis)

          -  More than one (1) lesion in target vessel

          -  Non-atherosclerotic stenosis (fibromuscular dysplasia)

          -  Excessive vessel tortuosity

          -  Lesion involving a side-branch

          -  Lesion in accessory renal artery

          -  Abdominal aortic aneurysm &gt; 3.5 cm

          -  Perforated vessels evidenced by extravasation of contrast media
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Grady, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krishna Rocha-Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prairie Cardiovascular Heart Institute, St. John's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital Care System</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peoria Radiology Associates Research &amp; Education Foundation</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education &amp; Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital &amp; Health Care Center, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Care Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South (CIS)</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYPH &amp; Trustees of Columbia University of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Health and Education Corp. d/b/a Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Heart Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAMC Institute</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rocha-Singh K, Jaff MR, Lynne Kelley E; RENAISSANCE Trial Investigators. Renal artery stenting with noninvasive duplex ultrasound follow-up: 3-year results from the RENAISSANCE renal stent trial. Catheter Cardiovasc Interv. 2008 Nov 15;72(6):853-62. doi: 10.1002/ccd.21749.</citation>
    <PMID>19006254</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal stent</keyword>
  <keyword>stent</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>aortorenal ostium</keyword>
  <keyword>renal</keyword>
  <keyword>renal artery</keyword>
  <keyword>PTRA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

